BLANCO, B.; GARCIA RUIZ, A. J.    GARCIA-AGUA SOLER, N.. Health outcomes and efficiency of fentanyl pectin intranasal breakthrough cancer pain in clinical practice. []. , 20, 5, pp.221-229. ISSN 1134-8046.  https://dx.doi.org/10.4321/S1134-80462013000500004.

Objective: Determine, with a pharmacoeconomic evaluation, the effectiveness and efficiency of fentanyl pectin intranasal spray for BTPc versus other indicated treatments. Results and conclusions: All the treatments analyzed in the pharmacoeconomic evaluation were cost-effective in terms of a willingness to pay (invest) of € 30,000 per AVAC gained (cost / effectiveness ratio < € 30,000). The most efficient option (greater effectiveness and lower cost) of all the treatments analyzed was the fentanyl pectin nasal spray (FPNS). In the incremental analysis FPNS was the dominant treatment option over all the others evaluated: FST, OTFC, FBT and INFS. From the analysis of the data of our cost/effectiveness modeling study of the fentanyl pectin nasal spray, FPNS, we can conclude: - INFS without providing greater effectiveness has been shown to be significantly more expensive (+15 %). - FST, OTFC, FBT have demonstrated -18 % less effectiveness and also been shown to be significantly more expensive than FPNS (+9 %; +15 %; +10 %, respectively). Abbreviations: AVAC: Years gained with good quality of life. FPNS: PecFent^®. FST: Abstral^®. OTFC: Actiq^®. FBT: Effentora^®. INFS: Instanyl^®.

: BreakThrough Cancer Pain; Fentanilo; pharmacoeconomic; cost-effectiveness.

        · |     · |     · ( pdf )